Antibody-Drug Conjugates and Linker Engineering 3

• 4423 · PDF Advancing ADC therapeutics with next-generation site-specific glycan conjugation and dual-payload flexibility Wei-Chien Tang, Yu-Hung Chen, Chih-Kang Chang, Ting-Wei Liu, Hung-Yi Lin, Wei-Jhen Huang, Chi-Huan Lu, Ren-Yu Hsu, Nan-Hsuan Wang, Ya-Chi Chen, Teng-Yi Huang
• 4424 · PDF Preclinical efficacy of a first-in-class anti-Integrin alpha/beta ADC in hard-to-treat solid tumors Qinhong Ma, Daizong Li, Kewei Zhao, Mary Q. Xu, Mason Lu
• 4426 Novel tumor microenvironment (TME)-activated, pan-RASi and Topo1i dual-payload linker enables safe broad RAS inhibition and overcomes Topo1i resistance Zhengsong Gu, Cheng Liu, Yuan Liu
• 4427 · PDF Development of CLIO-8221: A HER2-targeted multi-payload ADC to address ADC resistance Alyson Smith, Ben Ayers, Shalini Paliwal, Bhushan Dharmadhikari, Jerome Boyd-Kirkup
• 4430 · PDF WuXiTecan2: A hydrophilic exatecan linker-payload for dual-payload ADC discovery Hu Chen, Qirui Fan, Zili Xu, Xiaomei Li, Ding Wei, Lin Zhang, Chenghu Hu, Cindy Cheng, Marie Zhu
• 4431 · PDF ZW427, a Ly6E-targeting antibody drug conjugate bearing a novel pan-RAS inhibitor payload for the treatment of RAS mutated cancers Dunja Urosev, Vidhi Khanna, Ambroise Wu, Jodi Wong, Saki Konomura, Elizabeth Porter, Matthew Bonderud, Victoria Harman-McKenna, Taixiang Wang, Linglan Fu, Diego Alonzo, Devika Sim, Adele Chan, Allysha Bissessur, Spencer Boisjoli, Michael Lee, Germanna Righetto, Jesse Leblanc, Raffaele Colombo, Graham Garnett, Jamie Rich, Stuart Barnscher
• 4432 · PDF LNF2105, a next-generation nectin-4-targeted ADC with a specially designed linker and a DXD analogue Zhongsong Zhu, Shili Wang, Jinhua Xu, Fanliang Cheng, Yuqiang Zhu, Peibiao Zhang, Guimin Zhang, Lili Zhao, Zhenyu Li
• 4433 · PDF Preclinical evaluation of LM-364 TME : A next-generation anti-Nectin4 ADC with promising efficacy and reduced toxicity Lei Shi, Yun Zhang, Rongrong Huang, Xia Qin, Da Fei, Yuan Li, Wei Cao
• 4434 · PDF In vitro and in vivo study of C 2 LP-ADC & CLP 2 -ADC targeting human breast and gastric cancer Xingquan Ma, Greg Liang, Weihua Shi, Bing Li, Shuwei Lu, Xinxin Yang, Qikuan Chen, Guilan Wang, Yao Ma
• 4435 · PDF Transforming ADC development with novel linker architectures and payload optimization Gengcheng Jack Yang, Xudong Wei
• 4436 Sutro's site-specific dual-payload ADCs combining TOPO1i and DNA damage response inhibitors to enhance efficacy, overcome resistance, and improve safety Krishna Bajjuri, Robert Yuan, Daniel Calarese, Rhoneil Pena, Ravi Singh, Young Park, Cuong Tran, Abigail Yu, Xiaofan Li, Guifen Xu, Yihong Zhou, Brian Vuillemenot, Werner Rubas, Genevive Hernandez, Alice Yam, Gang Yin, Hans-Peter Gerber
• 4437 · PDF Preclinical development of XNW28012, an antibody drug conjugate targeting tissue factor for treatment of solid tumors Yonghan Hu, Zhe Zhang, Yuanbao Li, Liang Kong, Shihua Wang, Zhenwei Wu, Xiaocheng Hu, Ka Ruan, Wengui Wang, Guorong Li, Qifeng Shi, Haiyang Wei, Xiaojun Liu, Meijie Le, Jing Qiang
• 4438 · PDF A novel synergistic dual-payload TROP2 ADC (CTPH-03) delivering enhanced safety by increased MTD Myeong Joo Kim, Soyeon Lim, Dahyun Kim, Han ah Kim, Jaebeom Park, Eunseok Choi, Da wo Jeong, Ji Eun Choi, Young Sang Kim, Seung Chan Kim, Hyo Jin Kang, Chang-Sun Lee
• 4439 · PDF Preclinical assessment of HWK-007, a next-generation, PTK7-targeting ADC with novel bioconjugation and linker-payload technology Kathy S. Keegan, Shihe Hou, Ashwini B. Pai, Enrico Bellomo, Erik Kratzer, Victor Peykov, Bryan Ball, Xia Wang, Qingling Lu, Lei Wu, Jijie Gu, David J. Lennon, David Dornan
• 4440 Preclinical assessment of HWK-206, a next-generation, biparatopic, SEZ6-targeting ADC with novel bioconjugation and linker-payload technology Kathy S. Keegan, Shihe Hou, Ashwini B. Pai, Enrico Bellomo, Erik Kratzer, Victor Peykov, Bryan Ball, Lei Wu, Mengmeng Sun, Lu Jiang, Jijie Gu, David J. Lennon, David Dornan
• 4441 · PDF Preclinical characterization of novel LIV1 antibody drug conjugates Fei Teng, Huanhuan Guo, Xinlai Yao, Lizhi Qin, Lei Shi, Xu Lin, Yi Gu, Xueming Qian
• 4442 · PDF Targeting ITGB4 with a topoisomerase I ADC: Preclinical antitumor activity in colorectal and head and neck cancers Mi Young Cha, Hyunuk Kim, Hyunkyung Yu, Youngeun Ha, Kitae Park, Seungmin Byun, Bu-Nam Jeon, Mira Kim, Gyeongyeon Kim, Sangmoo Park, Wuhwui An, Suah Choi, Yura Kang, Hansoo Park
• 4443 · PDF Preclinical development of GENA-104 ADC, an exatecan-based novel antibody-drug conjugate targeting CNTN4, for solid tumors Mi Young Cha, Hyunkyung Yu, Hyunuk Kim, Kitae Park, Youngeun Ha, Seungmin Byun, Jiyeong Lee, Mira Kim, Bu-Nam Jeon, Soojung Moon, Gyeongyeon Kim, Gyeong-Jin Cheon, Hansoo Park
• 4444 · PDF Integrin alpha-2 (ITGA2) is a novel and well-suited antibody-drug conjugate (ADC) target Sophie Colombo, Vincent Martin, Aurélie Courtin, Sylvain Roqueviere, Lou-Amélia Revellin, Benjamin Beaufils, Catherine C. L. Wong, Pei Han, Wei Li, Yu Song, Qing Zhou, Feng He, Chuanying Xu, Weihong Nian, Mary Jane Hinrichs, Elisabetta Leo
• 4445 · PDF Diverse ADC novel payloads, comprehensive screening and evaluation platform Ying Meng, Qian Wang, Min Kang, Xuan Qiao, Chanrui Wang, Yixiao Zhao, Jiangtao Lin, Jiamei Zhao, Li Li, Tiejun Bing
• 4447 Next generation molecular tools for evaluating antibody drug conjugates in 3D systems Jayanth Surya Narayanan Shankara Narayanan, Ryan Holly
• 4448 · PDF 3D-tumor organoid, over 2D-cell, is more predictive of in vivo anti-cancer pharmacology in assessing ADC candidates Tao Yang, Jun Zhou, Hang Ke, Jessie Jingjing Wang, Jiawen Gao, Qing Li, Jinxi Wang, Feiyu Peng, Cen Chen, Lei Zhang, Faming Zhang, Henry Li
• 4449 · PDF Functional organoid screening uncovers target dependency and bystander killing in TROP2 ADCs Jialei Sun, Marten Hornsveld, Lenno Krenning, Dorrith Verstegen, Peng Han, Zhongman Sun, Caitlyn Hulsebosch, Dione Blok, Peter van Schaik, Mali He, Huike Ju, Yi Sun, Mariusz Madej, Hester Bange, Jun Zhou, Peng Wang, Ludovic Bourre, Marrit Putker

在完整检索应用中浏览本分会场 →